Summary
{ "trade_ideas": [], "tldr": { "summary": "The newsletter's market argument is that three catalysts — Unitree's record-setting humanoid IPO, Bitcoin's sharp rally on U.S. crypto-regulatory signals, and Moderna's successful Phase 3 cancer-vaccine trial — are repricing previously speculative themes toward public markets. For traders, the common thread is that explicit public-market proof points are emerging in humanoids, crypto infrastructure, and personalized mRNA.", "key_points": [ "Unitree closed up 460% at 845 yuan on its Shanghai STAR debut after pricing at 150.80 yuan, raising 6.1 billion yuan (~$904 million) and valuing the company at roughly $50.7 billion.", "Unitree shipped more than 5,500 humanoid robots in 2025, reported 1.7 billion yuan in revenue (4x 2024) and 278 million yuan in profit, making it one of the few profitable humanoid makers.", "Chinese manufacturers made roughly 90% of the ~16,000 humanoids shipped worldwide in 2025, and Morgan Stanley doubled its 2026 Chinese shipment forecast to 50,000 units.", "Bitcoin rose more than 24% to above $78,000 — its best weekly gain since March 2024 — as $2.74 billion of crypto shorts were liquidated in 24 hours